Professor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis.  He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.

Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). His Unit has one of the largest cohorts, if not the largest cohort, of homozygous FH patients in the world and has contributed and continues to contribute to the management of these patients. The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.


HoFH – can we move away from apheresis89th EAS Congress 2021PCSK9 inhibitor therapy - The cure for atherosclerosis?EAS AC in Lipidology